US Food and Drug Administration gives four observations to Gland Pharma plant near Hyderabad

Inspection Details

The United States Food and Drug Administration has issued four observations to a Gland Pharma formulation facility located near Hyderabad. These four Form 483 observations came after an unannounced inspection that checked current good manufacturing practice at the plant in Dundigal. The inspection took place between October 12 and October 23.

Company Response

Gland Pharma stated in a stock exchange filing on Friday, October 24, 2026, that these observations are procedural in nature. The company also confirmed that the points raised are neither repeat observations nor related to data integrity. Management noted that corrective and preventive actions will be sent to the US FDA within the required time frame. Following the announcement, Gland Pharma shares dropped 1.17 percent to close at ₹2,825.35 each on the BSE.

Context

Drug regulatory agencies like the US FDA routinely inspect manufacturing plants to make sure companies follow strict quality and safety rules. When inspectors find issues during a visit, they issue Form 483 notices so the company can fix the problems. Investors often react to regulatory scrutiny in the pharmaceutical sector because compliance issues can temporarily slow down product approvals.